openPR Logo
Press release

IoMT (Internet of Medical Things) to drive the Fibromyalgia Antidepressants Market

02-04-2022 01:24 PM CET | Health & Medicine

Press release from: Persistence Market Research

IoMT (Internet of Medical Things) to drive the Fibromyalgia

The Fibromyalgia Antidepressants Market is expected to grow on an irrevocable note in the upcoming period. The medical landscape is witnessing an influx of at-home diagnostic kits. This trend of on-demand products is likely to take the healthcare vertical by storm in the upcoming period. It has been observed that home kits aid in educating patients and bringing them to the medical visits better prepared, thereby curtailing the time taken for diagnosis. The status quo would help in keeping the healthcare vertical’s cash registers ringing going forward as well.
As per Persistence Market Research’s latest industry analysis, the global fibromyalgia antidepressants market was valued at US$ 440.8 Mn in 2020, and is expected to exhibit a healthy CAGR of 8.1% over the forecast period (2021-2031)

Rising prevalence of fibromyalgia caused due chronic back pain, previously associated spinal injury, trauma, osteoarthritis, road accidents, and musculoskeletal disorders are expected to drive demand for better treatment along with effective medications for fibromyalgia. Thus, demand for improved treatment with fibromyalgia antidepressants is expected to provide a positive impetus to market growth.

Treatment cost with branded drugs is significantly higher, and it is expected to remain high when compared with generic drugs or other off-label drugs. These higher costs will drive demand for generic drugs. The generic versions of these drugs are likely to see high demand in low-income economies or in economies where these products are limited or not available.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32898

Consolidation activities, mergers, and acquisitions have emerged as a key growth strategy among industry leaders. This trend is quite evident in key markets for fibromyalgia antidepressants.

For instance, the recent acquisition of Allergan plc by AbbVie Inc. in May 2020. This acquisition enabled AbbVie to strengthen its presence across key therapy areas, including immunology, hematologic oncology, and neuroscience.
Similarly, in June 2019, Eli Lily received FDA approval for its migraine drug Emgality, for its use in the treatment in management of cluster headaches.

Get a Customized Scope to Match Your Need Ask an Expert- sales@persistencemarketresearch.com

Company Profiles:

Pfizer, Inc.
Eli Lilly and Company.
AbbVie, Inc
TONIX Pharmaceuticals Holdings Corp
Virios Therapeutics, Inc.
Aptinyx Inc.

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/32898

Key Takeaways from Market Study

In terms of drug class, duloxetine HCL drug holds around 57.8% market value share. Growth is primarily attributed as duloxetine HCL mainly used to treat patients with diabetes and long-term chronic pain.
Based on distribution channel, hospitals pharmacies are leading with over 46% market share, as more patients are consulted at hospitals for fibromyalgia.
By region, North America is set dominate the global market with a value share of around 45.8% in 2021. Europe is slated to be the second-largest leading regional market with a value share of around 20.5% in 2021.
“Rising number of cases of fibromyalgia and better availability of fibromyalgia antidepressant medication are expected to drive market growth over the coming years,” says an analyst of Persistence Market Research.

Market Competition

New product launches and approvals, agreements, collaborations, and partnerships have emerged as key growth strategies adopted by industry players. By focusing on these strategies, key stakeholders are expanding their geographic footprints and strengthening their existing product portfolios.

In January 2021, Eli Lilly acquired pharmaceutical rights from Aashi Kahei Pharma of its experimental drug in early-stage testing for managing chronic pain.
In October 2020, Eli Lily entered into a collaboration agreement with Daichi Sankyo in Japan for the commercialization of Galcanezumab, an anti-CGRP antibody, which has potential use in the treatment of migrane.
In July 2019, FSD BioSciences, Inc. acquired a U.S.-based company Prismic Pharmaceuticals, which is engaged in developing novel therapies for fibromyalgia treatment.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/32898

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the fibromyalgia anti-depressants market in its latest study, presenting historical demand assessment of 2016 – 2020 and projections for 2021 – 2031.

The research study is based on the drug class (venlafaxine, duloxetine HCL, milnacipran HCL, and others), distribution channel (hospital pharmacies, retail pharmacies, drug stores, online sales), and seven key regions of the world.

Complete Report Details@ https://www.persistencemarketresearch.com/market-research/fibromyalgia-antidepressants-market.asp

Read More Trending "PMR Exclusive Article"-

Immune Repertoire Sequencing Market@ https://www.persistencemarketresearch.com/market-research/immune-repertoire-sequencing-market.asp

Life Science Market@ https://www.persistencemarketresearch.com/market-research/life-science-market.asp

Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com

About us-
Business intelligence is the foundation of every business model employed by Persistence Market Research. Multi-dimensional sources are being put to work, which include big data, customer experience analytics, and real-time data collection. Thus, working on “micros” by Persistence Market Research helps companies overcome their “macro” business challenges.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release IoMT (Internet of Medical Things) to drive the Fibromyalgia Antidepressants Market here

News-ID: 2545474 • Views: 184

More Releases from Persistence Market Research

Soy milk market Extends at a Healthy CAGR of 9.1% during forecast 2023 to 2033
The most recent market analysis conducted by Persistence Market Research on the global soy milk market industry evaluates opportunities and the state of the market while providing details and updates on the pertinent market segments for the forecast period of 2021-2031. The study provides a comprehensive analysis of the key market trends as well as detailed information on the makeup of the industry. In-depth details on the market's anticipated growth
Cassia Extract Market : US Poised to Achieve Continuing Growth| grow at a CAGR o …
In a new market research report on the global cassia extract market, Persistence Market Research evaluated the opportunities and the existing state of the market. Insights and updates on the pertinent market segments for the projected period of 2022-2032 are also provided in the study. The study provides a comprehensive analysis of the key market trends as well as detailed information on the makeup of the industry. This report goes
Brain Disease Market: Growth and Opportunity Ahead| Pfizer Inc., Eli Lilly, F. H …
Brain diseases, such as Alzheimer's, Parkinson's, and Multiple Sclerosis, are among the leading causes of death and disability worldwide. The increasing prevalence of brain diseases and the growing awareness about the importance of early diagnosis and treatment is driving the growth of the Brain Disease Market. The global brain disease market is segmented on basis of diseases, distribution channels and geography Disease  Brain Cancer  Alzheimer Disease  Alcoholism  Amnesia  Epilepsy  Meningitis  Others Distribution Channel  Hospitals Pharmacy  Online Pharmacy  Pharmacy 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝘁𝗵𝗲 𝘀𝗮𝗺𝗽𝗹𝗲 𝗰𝗼𝗽𝘆 𝗼𝗳 𝗿𝗲𝗽𝗼𝗿𝘁
Antioxidants Market expected to generate a revenue of  US$ 3.69 Bn by 2027 end, …
In a recent market research report, Persistence Market Research evaluated the potential and existing market conditions for the global antioxidants market. Insights and updates on the pertinent market segments for the anticipated period of 2021-2031 are also provided by the study. The study provides a comprehensive analysis of the key market trends as well as detailed information on the makeup of the industry. In-depth information on the market's anticipated growth

All 5 Releases


More Releases for Fibromyalgia

Fibromyalgia Treatment Market 2022 | Increased Morbidity of Fibromyalgia Along w …
According to Precision Business Insights (PBI), the latest report, the Fibromyalgia Treatment market is expected to be valued at USD 3,017.9 million in 2022, growing at an 3.8% CAGR from 2022 to 2028. Fibromyalgia treatment market analysis projects that the increased prevalence of fibromyalgia and its related complication compelled the introduction of targeted & precise treatment methods for fibromyalgia. Also, the increase in awareness about fibromyalgia will give the required
Fibromyalgia - Drug Pipeline Landscape, 2022
Fibromyalgia is a is a common chronic syndrome characterized by widespread musculoskeletal pain, fatigue, sleep, memory and cognitive issues. Researchers reported that repeated nerve stimulation causes the brain and spinal cord of people with fibromyalgia to change. The conditions conditions that may bring on symptoms, such as: stressors, viral infections or other illnesses like arthritis, anxiety, depression, other mood disorders, PTSD. Fibromyalgia can be diagnosed if the patient had widespread pain
Fibromyalgia Treatment Ingredient Market | 2021 Trends, Size, Share
The global fibromyalgia treatment market size is expected to reach USD 1,414.4 million by 2027, exhibiting a CAGR of 9.2% during the forecast period. Fibromyalgia Treatment Ingredient Industry is segmentedBy Product Type (Single Energy Mode, Dual Energy Mode), By Vehicle Type (Passenger Cars, Commercial Vehicles) and regional forecast 2021-2027 Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/fibromyalgia-treatment-market-105016 Strong Pipeline Products to Augment Growth The prominent companies are focused on introducing innovative therapies
Fibromyalgia Treatment Market Global Industry Insights 2018-2026
Fibromyalgia is a common and complex chronic pain disorder that causes musculoskeletal pain, fatigue and localized tenderness affecting individuals mentally, physically and socially. Fibromyalgia is mainly caused due to genetic conditions, however actual cause is still unknown. The most common symptoms of fibromyalgia are fatigue, sleeping problems, chronic muscle pain and tender points. An individual with fibromyalgia can also have symptoms such as headaches, poor concentration and depression. Fibromyalgia symptoms
Anticonvulsant Market for Fibromyalgia Optimistic Opportunities 2025
Anticonvulsant Market for Fibromyalgia: Snapshot Anticonvulsants are pharmacological agents from a diverse group that are used for the treatment of epileptic seizures. Anticonvulsants are increasingly in demand on account of their use for the treatment of bipolar disorders. They are also used for the treatment of borderline personality disorder. Anticonvulsants act as stabilizers of mood and helps in the treatment of neuropathic pain. They suppress the rapid, excessive firing of neurons
Chinese Fibromyalgia Market Research Report- Forecast to 2022
Market Scenario: Fibromyalgia syndrome is a condition characterized by widespread musculoskeletal pain. Patients with fibromyalgia may also have muscle stiffness, increased sensitivity to pain, problems with mental processes, fatigue, irritable bowel syndrome (IBS), and others. As symptoms of fibromyalgia syndrome mimic other chronic diseases, therefore its diagnosis takes a long time. According to a study published in Arthritis Research & Therapy journal in 2017, in Taiwan, the risk of coronary heart